HUP0203688A2 - N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent - Google Patents
N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agentInfo
- Publication number
- HUP0203688A2 HUP0203688A2 HU0203688A HUP0203688A HUP0203688A2 HU P0203688 A2 HUP0203688 A2 HU P0203688A2 HU 0203688 A HU0203688 A HU 0203688A HU P0203688 A HUP0203688 A HU P0203688A HU P0203688 A2 HUP0203688 A2 HU P0203688A2
- Authority
- HU
- Hungary
- Prior art keywords
- protein kinase
- pro
- receptor complex
- modification agent
- signal pathway
- Prior art date
Links
- 230000019491 signal transduction Effects 0.000 title abstract 4
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 3
- 102000020233 phosphotransferase Human genes 0.000 title abstract 3
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 title 1
- 101710108492 fMet-Leu-Phe receptor Proteins 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 108091006027 G proteins Proteins 0.000 abstract 3
- 102000030782 GTP binding Human genes 0.000 abstract 3
- 108091000058 GTP-Binding Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 210000000601 blood cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000003607 modifier Substances 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 230000007112 pro inflammatory response Effects 0.000 abstract 2
- 230000000770 proinflammatory effect Effects 0.000 abstract 2
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A találmány tárgya eljárás humán perifériás mononukleáris vagypolimorfonukleáris vérsejt, vagy rögzített szöveti sejt pro-inflammatorikus válaszának gátlására. A sejtet érintkezésbe hozzákpro-inflammatorikus szerrel proinflammatorikus válasz stimulálásavégett. Azután a sejtet érintkezésbe hozzuk G-protein-kinázjeltovábbítási útvonal módosítószerrel, ezáltal G-protein általközvetített gyulladási szignáltranszdukciós útvonalakat gátolnak. Atalálmány tárgya receptor-komplex, amelyben G-protein-kinázjeltovábbítási útvonal módosítószer kötődik pro-inflammatorikusszerrel stimulált humán perifériás mononukleáris vagypolimorfonukleáris vérsejt sejtfelszíni receptorához. ÓThe subject of the invention is a method for inhibiting the pro-inflammatory response of human peripheral mononuclear or polymorphonuclear blood cells or fixed tissue cells. The cell is contacted with a pro-inflammatory agent to stimulate a pro-inflammatory response. The cell is then exposed to a G-protein kinase signaling pathway modifier, thereby inhibiting G-protein-mediated inflammatory signal transduction pathways. The subject of the invention is a receptor complex in which a modifier of the G-protein kinase signaling pathway binds to the cell surface receptor of a human peripheral mononuclear or polymorphonuclear blood cell stimulated with a pro-inflammatory agent. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15967799P | 1999-10-15 | 1999-10-15 | |
| PCT/US2000/028183 WO2001029069A1 (en) | 1999-10-15 | 2000-10-12 | N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0203688A2 true HUP0203688A2 (en) | 2003-02-28 |
Family
ID=22573520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203688A HUP0203688A2 (en) | 1999-10-15 | 2000-10-12 | N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1222199A4 (en) |
| JP (1) | JP2004507441A (en) |
| KR (1) | KR20020057972A (en) |
| CN (1) | CN100497374C (en) |
| AU (1) | AU8014200A (en) |
| BR (1) | BR0014742A (en) |
| CA (1) | CA2387559A1 (en) |
| CZ (1) | CZ20021342A3 (en) |
| EA (1) | EA200200451A1 (en) |
| HU (1) | HUP0203688A2 (en) |
| IL (1) | IL149125A0 (en) |
| MX (1) | MXPA02003782A (en) |
| NO (1) | NO20021732L (en) |
| PL (1) | PL356096A1 (en) |
| WO (1) | WO2001029069A1 (en) |
| ZA (1) | ZA200202937B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| WO2004100978A1 (en) * | 2003-05-13 | 2004-11-25 | Medvet Science Pty. Ltd. | A method of modulating cellular transmigration and agents for use therein |
| JP4846799B2 (en) | 2005-07-05 | 2011-12-28 | バイオテンプト ベー．フェー． | Tumor treatment |
| EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| US20110082091A1 (en) * | 2009-09-28 | 2011-04-07 | Theramab Gmbh | Method for Preclinical Testing of Immunomodulatory Drugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516820A (en) * | 1997-11-13 | 2002-06-11 | ヒスタテク・エルエルシー | Low molecular weight peptides and methods of treating asthma and inflammation |
-
2000
- 2000-10-12 BR BR0014742-7A patent/BR0014742A/en not_active IP Right Cessation
- 2000-10-12 CN CNB008156867A patent/CN100497374C/en not_active Expired - Fee Related
- 2000-10-12 EP EP00970817A patent/EP1222199A4/en not_active Withdrawn
- 2000-10-12 WO PCT/US2000/028183 patent/WO2001029069A1/en active Application Filing
- 2000-10-12 KR KR1020027004714A patent/KR20020057972A/en not_active Application Discontinuation
- 2000-10-12 PL PL00356096A patent/PL356096A1/en not_active Application Discontinuation
- 2000-10-12 CZ CZ20021342A patent/CZ20021342A3/en unknown
- 2000-10-12 HU HU0203688A patent/HUP0203688A2/en unknown
- 2000-10-12 EA EA200200451A patent/EA200200451A1/en unknown
- 2000-10-12 IL IL14912500A patent/IL149125A0/en unknown
- 2000-10-12 JP JP2001531867A patent/JP2004507441A/en active Pending
- 2000-10-12 AU AU80142/00A patent/AU8014200A/en not_active Abandoned
- 2000-10-12 CA CA002387559A patent/CA2387559A1/en not_active Abandoned
- 2000-10-12 MX MXPA02003782A patent/MXPA02003782A/en not_active Application Discontinuation
-
2002
- 2002-04-12 NO NO20021732A patent/NO20021732L/en not_active Application Discontinuation
- 2002-04-15 ZA ZA200202937A patent/ZA200202937B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02003782A (en) | 2002-12-13 |
| CZ20021342A3 (en) | 2003-01-15 |
| WO2001029069A1 (en) | 2001-04-26 |
| KR20020057972A (en) | 2002-07-12 |
| EA200200451A1 (en) | 2002-10-31 |
| EP1222199A1 (en) | 2002-07-17 |
| IL149125A0 (en) | 2002-11-10 |
| CA2387559A1 (en) | 2001-04-26 |
| JP2004507441A (en) | 2004-03-11 |
| CN1633447A (en) | 2005-06-29 |
| CN100497374C (en) | 2009-06-10 |
| EP1222199A4 (en) | 2003-03-12 |
| NO20021732L (en) | 2002-06-12 |
| ZA200202937B (en) | 2003-09-23 |
| BR0014742A (en) | 2002-08-27 |
| NO20021732D0 (en) | 2002-04-12 |
| PL356096A1 (en) | 2004-06-14 |
| AU8014200A (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203688A2 (en) | N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent | |
| Roy et al. | Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet | |
| Horvath | Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous μ-opioid receptor agonists | |
| Duman et al. | Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. | |
| Di Prisco et al. | RANTES‐mediated control of excitatory amino acid release in mouse spinal cord | |
| AU2003213768A8 (en) | Use of benzimidazole analogs in the treatment of cell proliferation | |
| YU20600A (en) | This invention relates to the use of 5-ht3 receptor | |
| ID22216A (en) | USE OF CENTRANAN CANAGINOID ANTAGONISTS RECEPTORS TO CONTROL FOOD TREATMENT | |
| PT2260850T (en) | A2a receptor antagonists for use in the treatment of movement disorders | |
| MXPA03009185A (en) | Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson s disease. | |
| WO2005000240A3 (en) | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis | |
| Tang et al. | Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance | |
| ATE356994T1 (en) | SCREENING METHOD WITH PIM1-KINASE OR PIM3-KINASE | |
| Lissandron et al. | Compartmentalized cAMP/PKA signalling regulates cardiac excitation–contraction coupling | |
| ATE303439T1 (en) | INTRACELLULAR ISOFORM OF INTERLEUKIN-1 RECEPTOR ANTAGONIST | |
| EP1422240A3 (en) | Analogs of nociceptin | |
| WO2003106681A3 (en) | Antisense oligonucleotides against pim1 | |
| ITRM20030596A1 (en) | USE OF INHIBITORS OF LONG PTX3 PENTRAXINE, FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES WHICH REPLY TO THE INHIBITION OF THE BIOLOGICAL ACTIVITY OF ITS PTX3. | |
| DK1509523T3 (en) | Triazaspiro compounds useful for treating or preventing pain | |
| AU4856600A (en) | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder | |
| ATE400275T1 (en) | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF WORST LEGS SYNDROME OR NOcturnal MYOCLONUS | |
| Narita et al. | Up-regulation of spinal μ-opioid receptor function to activate G-protein by chronic naloxone treatment | |
| HUP0100105A2 (en) | Application of tnf antagonists as medicaments for treating septic diseases | |
| AU2003299540A8 (en) | Cells for determining the presence of a molecule that activates signal transduction activity of a cell surface protein | |
| IT1293557B1 (en) | PROCEDURE FOR CHECKING THE WATER LEVEL AND THE PRESENCE OF FOAM IN IMMERSED ELECTRODE HUMIDIFIERS. |